J Cancer 2019; 10(7):1601-1610. doi:10.7150/jca.27261 This issue

Research Paper

c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer

Ruting Xie1*, Yongzhi Yang2,3*, Huizhen Zhang4, Hu Liu1, Jing Guo1, Huanlong Qin5, Yanlei Ma2,3✉, Ajay Goel6✉, Xinxiang Li2,3✉, Qing Wei1✉

1. Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai200072, P.R. China.
2. Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China
3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
4. Department of Pathology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai200233, P.R. China.
5. Department of Surgery, Shanghai Tenth People's Hospital Affiliated with Tongji University, Shanghai 200072, P. R. China
6. Center for Translational Epigenomics and Oncology, Baylor Scott & White Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, United States.
*Yongzhi Yang and Ruting Xie contributed equally to this work

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Xie R, Yang Y, Zhang H, Liu H, Guo J, Qin H, Ma Y, Goel A, Li X, Wei Q. c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer. J Cancer 2019; 10(7):1601-1610. doi:10.7150/jca.27261. Available from https://www.jcancer.org/v10p1601.htm

File import instruction


Background: One of our previous studies have demonstrated that the cancer suppressor miR-150 regulated the progression of colorectal cancer (CRC) by down-regulating v-myb avian myeloblastosis viral oncogene homolog (c-Myb). The purpose of present study was to evaluate the prognostic value of the expression of c-Myb and its effector, prostaglandin-endoperoxide synthase 2 (COX-2) in patients with CRC.

Methods: We used tissue microarrays (containing 202 CRC tissues and matched adjacent normal tissues) and conducted immunohistochemical analysis and western blotting analysis (containing 3 CRC tissues and matched adjacent normal tissues) to detect the expression of c-Myb and COX-2.

Results: Compared with the adjacent nontumorous tissues, both the expression levels of c-Myb and COX-2 were higher in the cancer tissues. A statistically significant correlation was found between the expression of c-Myb and COX-2. Elevated c-Myb and COX-2 were associated with more advanced tumor invasion and poorer overall survival by univariate analysis. Higher expression levels of both c-Myb and COX-2 were significantly associated with shorter overall survival for stage II and stage III patients with 5-Fu based chemotherapy. Multivariate analysis identified the lymph node involvement, distant metastatic spread and the elevated c-Myb and COX-2 as independent factors of poor prognosis for CRC.

Conclusions: In conclusion, the overexpression of both c-Myb and COX-2 would be of prognostic screening value in patients with CRC.

Keywords: c-Myb, COX-2, colorectal cancer, prognosis